| Cat. No. |
Product Name |
Information |
| PC-38381 |
Nezulcitinib
pan JAK inhibitor
|
Nezulcitinib (TD-0903) is a inhaled lung-selective pan-JAK inhibitor, targets all JAK isoforms (JAK1, JAK2, JAK3, TYK2), Nezulcitinib is under development for treatment of acute lung injury associated with COVID-19. |
| PC-73438 |
Povorcitinib
JAK1 inhibitor
|
Povorcitinib (INCB054707) is a potent, selective and oral JAK1 inhibitor with IC50 of 8.9 nM, 52-fold selective over JAK2 (IC50=463 nM). |
| PC-73423 |
Ivarmacitinib
JAK1 inhibitor
|
Ivarmacitinib (SHR0302) is a potent highly selective, Janus kinase 1 (JAK1) inhibitor with IC50 of 0.1 nM, 9-fold selectivity over JAK2 and >70-fold over JAK3 and TYK2. |
| PC-73400 |
Atinvicitinib
JAK inhibitor
|
Atinvicitinib is a pyrazole compound and JAK inhibitor with IC50 of 0.4, 6 and 13 nM against JAK1, JAK2, and TYK2, less potent for JAK3 (IC50=1130 nM), has the potential for the research of atopic dermatitis. |
| PC-73205 |
Cerdulatinib hydrochloride
dual SYK/JAK inhibitor
|
Cerdulatinib (PRT062070) is a potent, ATP-competitive, orally active dual SYK/JAK inhibitor with IC50 of 32 nM (Syk), 0.5-12 nM (JAK1/2/3, Tyk2). |
| PC-73204 |
Cerdulatinib
Dual SYK/JAK inhibitor
|
Cerdulatinib (PRT062070) is a potent, ATP-competitive, orally active dual SYK/JAK inhibitor with IC50 of 32 nM (Syk), 0.5-12 nM (JAK1/2/3, Tyk2). |
| PC-73190 |
Baricitinib
JAK1/JAK2 inhibitor
|
Baricitinib (LY3009104, INCB028050) is a potent, selective and orally bioavailable JAK1/JAK2 inhibitor with IC50 of 5.9/5.7 nM, respectively. |
| PC-73064 |
LAS194046
pan-JAK inhibitor
|
LAS194046 (LAS-194046) is a potent, selective pan-JAK inhibitor with IC50 of 5.46/0.4/ 2.07 nM against JAK1/2/3, less potent in TYK2 activity (IC50=21.8 nM). |
| PC-73037 |
Deucravacitinib
TYK2 inhibitor
|
BMS-986165 (Deucravacitinib, BMS986165) is potent, high selective allosteric inhibitor of TYK2 with Ki of 0.02 nM, IC50 of 0.2 nM. |
| PC-72613 |
Ropsacitinib
TYK2 inhibitor
|
Ropsacitinib (PF-06826647) is a potent, selective TYK2 inhibitor with IC50 of 15 nM, inhibits JAK1/2/3 with IC50 of 383/74/>10,000 nM. |
| PC-72603 |
AZD4604
JAK1 inhibitor
|
AZD4604 (Londamocitinib, AZD-4604) is a, potent, highly selective, ATP-competitive and oral JAK1 inhibitor with IC50 of 0.54 nM, shows >1000-fold selectivity over other JAK family members. |
| PC-72341 |
TD-1473
Pan-JAK inhibitor
|
TD-1473 (Izencitinib, TD1473, JNJ 8398) is a potent, selective, oral gut-selective pan-JAK inhibitor with pKi of 10.0/10.0/8.8/9.5 for human recombinant JAK1, JAK2, JAK3 and TYK2. |
